ATE416175T1 - 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen - Google Patents

2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen

Info

Publication number
ATE416175T1
ATE416175T1 AT02712572T AT02712572T ATE416175T1 AT E416175 T1 ATE416175 T1 AT E416175T1 AT 02712572 T AT02712572 T AT 02712572T AT 02712572 T AT02712572 T AT 02712572T AT E416175 T1 ATE416175 T1 AT E416175T1
Authority
AT
Austria
Prior art keywords
treatment
arylaminopyrimidines
gsk3
related diseases
solution
Prior art date
Application number
AT02712572T
Other languages
English (en)
Inventor
Stefan Berg
Ratan Bhat
Sven Hellberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE416175T1 publication Critical patent/ATE416175T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AT02712572T 2001-02-20 2002-02-18 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen ATE416175T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26990301P 2001-02-20 2001-02-20

Publications (1)

Publication Number Publication Date
ATE416175T1 true ATE416175T1 (de) 2008-12-15

Family

ID=23029104

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02712572T ATE416175T1 (de) 2001-02-20 2002-02-18 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen

Country Status (16)

Country Link
US (1) US7078410B2 (de)
EP (1) EP1423388B1 (de)
JP (1) JP4309657B2 (de)
KR (1) KR20030076688A (de)
CN (1) CN100415744C (de)
AT (1) ATE416175T1 (de)
BR (1) BR0207096A (de)
CA (1) CA2435177A1 (de)
DE (1) DE60230160D1 (de)
ES (1) ES2316546T3 (de)
IL (1) IL156784A0 (de)
MX (1) MXPA03007266A (de)
NO (1) NO20033677L (de)
NZ (1) NZ527009A (de)
WO (1) WO2002066480A2 (de)
ZA (1) ZA200306175B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
AU2003302588A1 (en) * 2002-12-03 2004-06-23 Kyorin Pharmaceutical Co., Ltd. Phosphodiesterase 10a inhibitors
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2005037199A2 (en) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0402277D0 (en) * 2004-02-03 2004-03-10 Astrazeneca Ab Chemical compounds
JP2008515986A (ja) * 2004-10-13 2008-05-15 ワイス Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
MX2007007272A (es) * 2004-12-17 2007-07-11 Astrazeneca Ab 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
US20060204980A1 (en) * 2004-12-28 2006-09-14 Altieri Dario C Colorectal cancer therapies
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
BRPI0609802A2 (pt) * 2005-05-20 2017-05-02 Alantos Pharmaceuticals Holding Inc composto, composição farmacêutica e uso de um composto
BRPI0610876B8 (pt) 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20080214560A1 (en) * 2005-10-03 2008-09-04 Astrazeneca Ab Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
GB0520958D0 (en) 2005-10-14 2005-11-23 Cyclacel Ltd Compound
MX2008012617A (es) * 2006-03-31 2008-10-10 Novartis Ag Compuestos organicos.
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
CA2654670A1 (en) * 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
EP2102194A1 (de) * 2006-12-08 2009-09-23 F. Hoffmann-Roche AG Substituierte pyrimidine und ihre verwendung als jnk-modulatoren
HRP20150642T1 (hr) 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
US8067409B2 (en) 2007-11-27 2011-11-29 Abbott Laboratories Protein kinase inhibitors
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010002985A1 (en) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
CA2729909A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
UY32203A (es) * 2008-10-29 2010-05-31 Astrazeneca Ab Amino pirimidinas y su uso en terapia
CN101735211B (zh) * 2008-11-04 2012-11-14 复旦大学 2,3-二氢[1,5]苯并噻氮杂*类化合物或其盐在制备GSK-3β抑制剂中的用途
US20120077813A1 (en) 2009-04-15 2012-03-29 Astrazeneca Ab Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
CN102391264A (zh) * 2011-09-21 2012-03-28 河北九派制药有限公司 6-溴咪唑并[1,2-a]吡啶的制备方法
EP2671885A1 (de) * 2012-06-05 2013-12-11 Ares Trading S.A. Imidazo-Oxadiazol- und Imidazo-Thiadiazolderivate
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
JP6430383B2 (ja) * 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
NZ746607A (en) 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN106362155A (zh) * 2016-10-08 2017-02-01 无锡汉强医药科技有限公司 Gsk3抑制剂在制备治疗尼曼匹克病c型疾病中的应用
EP3555050A1 (de) 2016-12-16 2019-10-23 Basf Se Pestizidverbindungen
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
EP3836932A2 (de) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Verfahren zur behandlung von bauchspeicheldrüsenkrebs
KR102249521B1 (ko) 2018-11-14 2021-05-07 아이알링크 주식회사 스마트폰과 동기화되는 pc 인터페이스 장치 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2087056T3 (es) 1986-01-13 1996-07-16 American Cyanamid Co 2-pirimidinaminas sustituidas en las posiciones 4, 5 y 6.
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
AU9502601A (en) 2000-09-06 2002-03-22 Chiron Corp Inhibitors of glycogen synthase kinase 3

Also Published As

Publication number Publication date
WO2002066480A2 (en) 2002-08-29
DE60230160D1 (de) 2009-01-15
EP1423388B1 (de) 2008-12-03
JP2004522777A (ja) 2004-07-29
ZA200306175B (en) 2005-01-26
CN100415744C (zh) 2008-09-03
US20040106574A1 (en) 2004-06-03
EP1423388A2 (de) 2004-06-02
MXPA03007266A (es) 2003-12-04
NO20033677L (no) 2003-10-02
US7078410B2 (en) 2006-07-18
CA2435177A1 (en) 2002-08-29
ES2316546T3 (es) 2009-04-16
WO2002066480A3 (en) 2004-04-01
NO20033677D0 (no) 2003-08-19
KR20030076688A (ko) 2003-09-26
BR0207096A (pt) 2004-01-20
JP4309657B2 (ja) 2009-08-05
HK1094697A1 (zh) 2007-04-04
IL156784A0 (en) 2004-02-08
CN1823064A (zh) 2006-08-23
NZ527009A (en) 2006-04-28

Similar Documents

Publication Publication Date Title
DE60230160D1 (de) 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen
ATE545660T1 (de) Verfahren zur herstellung von niedermolekularem kationischem polygalactomannan mit verringertem geruch
DE60222420D1 (de) Verfahren zur hydrolyse von milcheiweissen
BR0108734A (pt) Composições antimicrobiais ácidas para tratar alimento e superfìcies de contato do alimento e métodos para uso das mesmas
DE59603187D1 (de) Verfahren zur herstellung von organisch modifizierten aerogelen, bei dem die gebildeten salze ausgefällt werden
ATE268124T1 (de) Flüssige chitosan-enthaltende zusammensetzungen und verfahren zur herstellung und verwendung
DE60013271D1 (de) Verfahren zur herstellung von verzweigten, löslichen glukose-polymerisaten
DE60107252D1 (de) Antimikrobielle zusammensetzung zur behandlung von rindermastitis
ATE355861T1 (de) Verfahren zur herstellung von absorbierenden sanitärartikeln mit milchsäure produzierenden bakterien
DE69807818D1 (de) Mittel zum eintauchen von zitzen
ATE360637T1 (de) Verfahren zur herstellung von polyphenolischen adhäsionsproteinen
DE60234032D1 (de) Verfahren zur herstellung von chitosan
ATE460175T1 (de) Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendung
ES2026314A6 (es) Procedimiento para obtener una composicion profilactica antimicrobiana oftalmica neonatal.
DE60220193D1 (de) Einwertiges salz verbessert die löslichkeit von milchproteinkonzentrat
FR2866890B1 (fr) Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
WO2002067952A8 (en) Prophylactic teat treatment
ATE233562T1 (de) Verwendung von hyaluronsäure zur herstellung einer wässrigen lösung verwendbar als intra- artikulare reinigungslösung
SE0101307D0 (sv) An effervescent solid composition of matter
KR960030812A (ko) 취반용 기능미의 제조방법
BRPI0416427A (pt) suspensão aquosa e método de preparação de suspensão aquosa
NO20033705L (no) Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr
JPS632911A (ja) 防カビ剤
NO20033707D0 (no) Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr
NO20033706L (no) Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties